Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

Current Articles

2024, Volume 42,  Issue 11

Cover Catalogue
Display Method:
Reviews
Progress on the treatment of sepsis
SONG Zecheng, CHEN Linlin, LU Renyi, LIU Mengxiao, WANG Yan
2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
Abstract(4970) HTML (1391) PDF (1208KB)(85)
Abstract:
Sepsis is a severe and life-threatening symptom that poses a significant risk to human health. Treatment mainly involves supportive care, but research on new drugs is ongoing. Advancements have been achieved in the management of immune function, inflammatory pathway, blood coagulation, and vascular endothelial homeostasis in sepsis. The advances in the treatment of sepsis in recent years were these reviewed in this article.
Original articles
Identification and expression pattern analysis of FBXL gene family in Salvia miltiorrhiza
YAO Ruiyang, YU Haizheng, LI Yaoxin, ZHANG Lei
2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
Abstract(358) HTML (133) PDF (3972KB)(2)
Abstract:
  Objective   To identify and analyze the bioinformatics and expression patterns of the F-box-LRR(FBXL) gene family of Salvia miltiorrhiza based on genomic data, and provide a foundation for further elucidating its gene functions.   Methods  The SmFBXL gene was identified from the Salvia miltiorrhiza genomic database. Its gene structure features, promoter cis-acting elements, physicochemical properties of encoded proteins, evolutionary relationships, and tissue expression were analyzed by bioinformatics methods and online tools.   Results  A total of 104 SmFBXL genes were identified from the Salvia miltiorrhiza genome, unevenly distributed on 8 chromosomes, with upstream promoters containing cis-acting elements related to plant stress resistance, growth and development, and hormone response. A phylogenetic tree of the FBXL family members of Salvia miltiorrhiza, Arabidopsis thaliana, and Glycine max was constructed, dividing the 104 SmFBXL genes into 7 subfamilies. Through homologous evolution analysis, it was speculated that SmFBXL36 might be involved in defense against pathogen invasion, SmFBXL86 and SmFBXL79 might play important roles in regulating lateral root growth in Salvia miltiorrhiza, and SmFBXL11 and SmFBXL40 might regulate hypocotyl growth. Transcriptome data showed differential expression of SmFBXL genes in different tissues of Salvia miltiorrhiza, with 13 SmFBXL genes showing higher expression levels in roots and leaves, serving as candidate genes for further research on the SmFBXL gene family.   Conclusion  The research results provided a reference for further elucidating the regulatory mechanisms of SmFBXL genes in stress response and secondary metabolite biosynthesis in Salvia miltiorrhiza.
Study on the potential mechanism of JQQSG for the treatment of CAP based on network pharmacology and molecular docking technology
CHEN Jintao, QIAO Ziying, MA Minghua, ZHANG Ruoxi, WANG Zhenwei, NIAN Hua
2024, 42(11): 471-478. doi: 10.12206/j.issn.2097-2024.202312014
Abstract(5452) HTML (1941) PDF (2177KB)(66)
Abstract:
  Objective  To investigate the possible mechanism of action of Jinqi Qingshu granules (JQQSG) in the treatment of community-acquired pneumonia (CAP) by network pharmacology and molecular docking technology.   Methods  The TCMSP database and SwissTargetPrediction database were used to obtain and screen the active ingredients and targets of JQQSG, and GeneCards, OMIM, TTD, and DisGeNET databases were used to search for the predicted targets of CAP, and the two targets were mapped and then imported into STRING database to construct a PPI network to screen the key targets, and then the GO and KEGG pathway enrichment were analyzed by the DAVID database, and molecular docking was carried out by the AutoDock Tools software.   Results  209 active ingredients and 1041 targets of JQQSG were obtained after screening; 312 targets were co-activated with CAP, and 64 core targets were obtained after PPI network screening. 571 biological processes, 68 cellular components, and 199 molecular functions were analyzed by GO enrichment, and 165 KEGG pathways were analyzed by KEGG pathway enrichment, mainly involved in protein action, apoptosis and MAPK signaling pathway. Molecular docking suggests that the core target and the core components all have good binding ability.   Conclusion  The mechanism of action of JQQSG in the treatment of CAP may be related to its regulation of Akt, MAPK signaling pathway, improvement of oxidative stress, and other pathways to exert anti-inflammatory and antioxidant effects, which could lay the foundation for further in-depth study of its specific mechanism of action.
Mechanism of effective ingredients of Dingqing tablets in the treatment of leukemia based on network pharmacology and molecular docking technology
CHEN Jing, HE Ruihua, WENG Yue, XU Yi, LIU Jing, HUANG Jin
2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
Abstract(1973) HTML (533) PDF (3370KB)(27)
Abstract:
  Objective  To explore the material basis and mechanism of the Chinese medicine Dingqing tablets in the treatment of leukemia.   Methods  The potential active ingredients of Dingqing tablets were retrieved through TCMSP and HERB Database and the targets of herbs were screened by Swiss TargetPrediction databases. The treatment targets of leukemia were searched from the GeneCards, OMIM and Disgenet databases. The protein-protein interaction network was used to construct the interactive target regulation function of Dingqing tablets and leukemia by STRING software, and the core subnetworks were filtered by the MCODE plug-in. A component-target pathway network was constructed by GO and KEGG enrichment analysis of the highest scoring Gene cluster 1 gene in the DAVID database. Molecular docking of the active components and core targets of Dingqing tablets was performed by AutoDock and the results were visualized.   Results  A total of 82 active ingredients and 439 targets of action of Dingqing tablets, and 1 878 leukemia-related targets were obtained through database retrieval, in which 169 common targets of active ingredients and diseases were mapped. Based on the degree values, the main active ingredients were determined as quercetin, luteolin, kaempferol, etc. The PPI core network indicated that the key targets for treating leukemia included TP53, MMP9, TNF, AKT1, CASP3, etc. The gene enrichment analysis of sub-networks and the component-target pathway network diagram showed that Dingqing tablets might exert therapeutic effects on leukemia by regulating signaling pathways such as TNF and IL-17. The molecular docking results showed fairly strong binding activity between the active ingredients and the targets.  Conclusion  The active ingredients of Dingqing tablets may participate in TNF, IL-17, and other signaling pathways by regulating genes such as TP53, AKT1, and CASP3, thereby exerting therapeutic effects on leukemia.
Effects of MT-1207 on blood glucose, blood lipids and atherosclerosis in mice
ZHANG Xiuping, TIAN Jiasheng, WANG Daoxin, LI Jiaxin, WANG Pin, MIAO Chaoyu
2024, 42(11): 487-494. doi: 10.12206/j.issn.2097-2024.202306011
Abstract(4678) HTML (1384) PDF (1685KB)(7)
Abstract:
  Objective  To study the effect of MT-1207 on blood glucose, blood lipids and atherosclerosis in mice.   Methods  The apolipoprotein E knockout (ApoE-/-) mice were fed with normal feed, drug feed containing losartan and drug feed containing MT-1207 at a dosage of 30 mg/kg. The body weight, blood glucose and blood lipids were detected, and the plaque area of atherosclerotic was evaluated. 8-week-old male C57 mice were fed a high fat diet and given intragastric administration of MT-1207 and losartan at a dose of 30 mg/kg per day. The body weight, blood glucose and lipids levels were also examined to further evaluate the effects of MT-1207 on blood glucose and lipids levels.   Results  ApoE-/- mice treated with MT-1207 and losartan gained weight faster. There was no significant improvement in blood glucose and lipid levels, and no significant change in atherosclerotic plaque area. MT-1207 and losartan had no significant improvement effect on blood glucose and blood lipids of C57 mice.   Conclusion  MT-1207 and losartan couldn’t improve the levels of blood glucose, blood lipids and atherosclerosis, and couldn’t aggravate atherosclerosis.
Optimization of the preparation process for lenvatinib mixed micelles by central composite design-response surface methodology
KAILIBINUER Aobuliaisan, LI Qian, XIE Zhi, JIA Wenyan, YIN Dongfeng
2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
Abstract(1599) HTML (1091) PDF (1395KB)(5)
Abstract:
  Objective  To optimize the formulation and preparation process of lenvatinib mixed micelles.   Methods  Hybrid micelles of lenvatinib were prepared by film hydration method, with Pluronic P123 and F127 as carrier materials. Optimal formulation was selected through single-factor experiments and central composite design-response surface methodology, and preliminary characterization of its physical properties was conducted.   Results  The optimized formulation and process conditions were identified as follows: P123 mass percentage of 80%, carrier material amount of 90 mg, drug loading of 10 mg, hydration volume of 6 ml, hydration time of 45 min, and rotary evaporation temperature of 55℃. The resulting lenvatinib mixed micelles had an average particle size of (104.0±0.32) nm, a polydispersity index (PDI) of 0.22±1.19, and a Zeta potential of (−2.56±0.81) mV. The average encapsulation efficiency was 83.33%±0.30% and the average drug loading was 8.67%±0.07%. The micelles displayed a uniform spherical morphology with a certain sustained-release capability.   Conclusion  The preparation process developed in this study was simple and feasible and produced drug-loaded micelles with high drug loading and encapsulation rates, and stable release, which could provide valuable insights for further research and development of lenvatinib mixed micelles.